Relmada Therapeutics, Inc.

News

Latest Press Releases, Articles & Media Resources

Press Releases

June 27, 2018
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder

Top-line Data Expected in First Half of 2019 NEW YORK, June 27, 2018 /PRNewswire/ --┬áRelmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the dosing of the first patient in the Company's Phase 2 clinical study to evaluate the safety and efficacy of REL-1017 (dextromethadone) as an… Read More ┬╗

More Press Releases